Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APLS Apellis Pharmaceuticals	$27.62 +3.9%	$20.61	$16.10 ▼ $41.94	$3.49B	0.78	2.31 million shs	2.00 million shs
MLTX MoonLake Immunotherapeutics	$54.17 +0.1%	$50.07	$31.42 ▼ $58.26	$3.48B	1.27	475,968 shs	435,402 shs
PTGX Protagonist Therapeutics	$56.04 -0.3%	$54.13	$33.31 ▼ $60.60	$3.49B	2.33	930,379 shs	500,857 shs
TRVI Trevi Therapeutics	$7.49 +0.9%	$6.76	$2.36 ▼ $8.11	$912.13M	0.58	1.81 million shs	2.30 million shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APLS Apellis Pharmaceuticals	-0.37%	0.00%	+37.86%	+49.49%	-31.76%
MLTX MoonLake Immunotherapeutics	+2.81%	-2.71%	+1.06%	+40.59%	+9.40%
PTGX Protagonist Therapeutics	-0.04%	-0.86%	+1.83%	+22.48%	+35.49%
TRVI Trevi Therapeutics	+1.37%	-2.37%	+8.80%	+23.05%	+160.35%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APLS Apellis Pharmaceuticals	4.5172 of 5 stars	4.3	1.0	4.4	3.3	2.5	0.6
MLTX MoonLake Immunotherapeutics	1.5903 of 5 stars	3.4	1.0	0.0	1.0	2.5	0.0
PTGX Protagonist Therapeutics	1.976 of 5 stars	2.5	3.0	0.0	3.1	2.5	0.0
TRVI Trevi Therapeutics	3.1032 of 5 stars	4.6	1.0	0.0	2.8	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APLS Apellis Pharmaceuticals	2.58	Moderate Buy	$34.12	23.59% Upside
MLTX MoonLake Immunotherapeutics	2.78	Moderate Buy	$74.43	37.55% Upside
PTGX Protagonist Therapeutics	3.00	Buy	$67.20	20.01% Upside
TRVI Trevi Therapeutics	3.20	Buy	$20.11	169.01% Upside

Current Analyst Ratings Breakdown

Latest TRVI, APLS, MLTX, and PTGX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2025	TRVI Trevi Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$18.00
8/8/2025	TRVI Trevi Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Strong-Buy ➝ Strong-Buy	$29.00 ➝ $27.00
8/8/2025	TRVI Trevi Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$24.00 ➝ $22.00
8/7/2025	PTGX Protagonist Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
8/7/2025	PTGX Protagonist Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$67.00 ➝ $69.00
8/6/2025	MLTX MoonLake Immunotherapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$74.00 ➝ $82.00
8/4/2025	APLS Apellis Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$35.00 ➝ $37.00
8/1/2025	APLS Apellis Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$17.00 ➝ $19.00
8/1/2025	APLS Apellis Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$39.00 ➝ $40.00
8/1/2025	APLS Apellis Pharmaceuticals	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$52.00 ➝ $50.00
7/29/2025	APLS Apellis Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$41.00 ➝ $46.00

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APLS Apellis Pharmaceuticals	$781.37M	4.46	N/A	N/A	$1.24 per share	22.26
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	$5.57 per share	N/A
PTGX Protagonist Therapeutics	$434.43M	8.02	$4.50 per share	12.45	$10.74 per share	5.21
TRVI Trevi Therapeutics	N/A	N/A	N/A	N/A	$1.63 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APLS Apellis Pharmaceuticals	-$197.88M	-$1.82	N/A	N/A	N/A	-30.24%	-116.09%	-26.72%	11/4/2025 (Estimated)
MLTX MoonLake Immunotherapeutics	-$118.94M	-$2.78	N/A	N/A	N/A	N/A	-40.98%	-35.81%	11/6/2025 (Estimated)
PTGX Protagonist Therapeutics	$275.19M	$0.70	80.00	N/A	N/A	24.88%	8.12%	7.41%	11/6/2025 (Estimated)
TRVI Trevi Therapeutics	-$47.91M	-$0.42	N/A	N/A	N/A	N/A	-41.44%	-38.21%	11/5/2025 (Estimated)

Latest TRVI, APLS, MLTX, and PTGX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	TRVI Trevi Therapeutics	-$0.10	-$0.09	+$0.01	-$0.09	N/A	N/A
8/6/2025	Q2 2025	PTGX Protagonist Therapeutics	-$0.53	-$0.55	-$0.02	-$0.55	$8.32 million	$5.55 million
8/5/2025	Q2 2025	MLTX MoonLake Immunotherapeutics	-$0.73	-$0.87	-$0.14	-$0.87	N/A	N/A
7/31/2025	Q2 2025	APLS Apellis Pharmaceuticals	-$0.44	-$0.33	+$0.11	-$0.33	$187.91 million	$171.39 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APLS Apellis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	N/A
PTGX Protagonist Therapeutics	N/A	N/A	N/A	N/A	N/A
TRVI Trevi Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APLS Apellis Pharmaceuticals	2.90	3.77	3.16
MLTX MoonLake Immunotherapeutics	0.21	16.65	16.65
PTGX Protagonist Therapeutics	N/A	16.97	16.97
TRVI Trevi Therapeutics	N/A	22.42	22.42

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APLS Apellis Pharmaceuticals	96.29%
MLTX MoonLake Immunotherapeutics	93.85%
PTGX Protagonist Therapeutics	98.63%
TRVI Trevi Therapeutics	95.76%

Insider Ownership

Company	Insider Ownership
APLS Apellis Pharmaceuticals	6.50%
MLTX MoonLake Immunotherapeutics	12.02%
PTGX Protagonist Therapeutics	4.90%
TRVI Trevi Therapeutics	18.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APLS Apellis Pharmaceuticals	770	126.29 million	118.08 million	Optionable
MLTX MoonLake Immunotherapeutics	2	64.23 million	56.51 million	Optionable
PTGX Protagonist Therapeutics	120	62.21 million	59.16 million	Optionable
TRVI Trevi Therapeutics	20	121.78 million	99.49 million	Optionable

TRVI, APLS, MLTX, and PTGX Headlines

Recent News About These Companies

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives $20.38 Average Price Target from Analysts

August 20 at 3:01 AM | americanbankingnews.com

B. Riley Boosts Earnings Estimates for Trevi Therapeutics

August 19 at 2:29 AM | marketbeat.com

B. Riley Increases Earnings Estimates for Trevi Therapeutics

August 19 at 2:17 AM | americanbankingnews.com

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Shares Sold by XTX Topco Ltd

August 17, 2025 | marketbeat.com

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Rating of "Buy" from Analysts

August 16, 2025 | marketbeat.com

Persistent Asset Partners Ltd Makes New $260,000 Investment in Trevi Therapeutics, Inc. (NASDAQ:TRVI)

August 13, 2025 | marketbeat.com

Informed Momentum Co LLC Invests $3.47 Million in Trevi Therapeutics, Inc. (NASDAQ:TRVI)

August 13, 2025 | marketbeat.com

Trevi Therapeutics: Optimism Amid Earnings Call Insights

August 13, 2025 | msn.com

Analysts Offer Insights on Healthcare Companies: Trevi Therapeutics (TRVI), DENTSPLY SIRONA (XRAY) and Arrowhead Pharmaceuticals (ARWR)

August 13, 2025 | theglobeandmail.com

HC Wainwright Analysts Increase Earnings Estimates for TRVI

August 12, 2025 | marketbeat.com

Trevi Therapeutics (NASDAQ:TRVI) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPS

August 11, 2025 | marketbeat.com

Needham & Company LLC Issues Pessimistic Forecast for Trevi Therapeutics (NASDAQ:TRVI) Stock Price

August 11, 2025 | americanbankingnews.com

Raymond James Financial Issues Pessimistic Forecast for Trevi Therapeutics (NASDAQ:TRVI) Stock Price

August 10, 2025 | marketbeat.com

Trevi Therapeutics (NASDAQ:TRVI) Is In A Good Position To Deliver On Growth Plans

August 10, 2025 | finance.yahoo.com

Needham & Company LLC Lowers Trevi Therapeutics (NASDAQ:TRVI) Price Target to $22.00

August 9, 2025 | marketbeat.com

Trevi Therapeutics, Inc. (TRVI) Q2 2025 Earnings Call Transcript

August 8, 2025 | seekingalpha.com

Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

August 7, 2025 | prnewswire.com

41,987 Shares in Trevi Therapeutics, Inc. (NASDAQ:TRVI) Bought by BIT Capital GmbH

August 4, 2025 | marketbeat.com

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Short Interest Up 6,352.7% in July

August 2, 2025 | marketbeat.com

Trevi Therapeutics (TRVI) Projected to Post Quarterly Earnings on Thursday

August 2, 2025 | marketbeat.com

Trevi Therapeutics (NASDAQ:TRVI) Stock Price Down 0.1% - Here's What Happened

August 1, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRVI, APLS, MLTX, and PTGX Company Descriptions

Apellis Pharmaceuticals NASDAQ:APLS

$27.62 +1.04 (+3.91%)

Closing price 04:00 PM Eastern

Extended Trading

$27.54 -0.09 (-0.31%)

As of 06:16 PM Eastern

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

MoonLake Immunotherapeutics NASDAQ:MLTX

$54.17 +0.03 (+0.06%)

Closing price 04:00 PM Eastern

Extended Trading

$53.62 -0.55 (-1.02%)

As of 06:06 PM Eastern

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

Protagonist Therapeutics NASDAQ:PTGX

$56.04 -0.19 (-0.34%)

Closing price 04:00 PM Eastern

Extended Trading

$55.58 -0.45 (-0.81%)

As of 07:13 PM Eastern

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Trevi Therapeutics NASDAQ:TRVI

$7.49 +0.07 (+0.94%)

Closing price 04:00 PM Eastern

Extended Trading

$7.37 -0.12 (-1.59%)

As of 07:30 PM Eastern

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time